Literature DB >> 16601094

Extracellular thioredoxin levels are increased in patients with acute lung injury.

M E Callister1, A Burke-Gaffney, G J Quinlan, A G Nicholson, R Florio, H Nakamura, J Yodoi, T W Evans.   

Abstract

BACKGROUND: Acute lung injury (ALI) and its extreme manifestation the acute respiratory distress syndrome (ARDS) complicate a wide variety of serious medical and surgical conditions. Thioredoxin is a small ubiquitous thiol protein with redox/inflammation modulatory properties relevant to the pathogenesis of ALI. We therefore investigated whether thioredoxin is raised extracellulary in patients with ALI and whether the extent of any increase is dependent upon the nature of the precipitating insult.
METHODS: Bronchoalveolar lavage (BAL) fluid and plasma samples were collected from patients with ALI (n=30) and healthy controls (n=18, plasma; n=14, BAL fluid). Lung tissue was harvested from a separate group of patients and controls (n=10). Thioredoxin was measured by ELISA in fluids and by immunohistochemistry in tissue. Interleukin (IL)-8 levels were determined by ELISA. Disease severity was assessed as APACHE II and SOFA scores.
RESULTS: BAL fluid levels of thioredoxin were higher in patients with ALI than in controls (median 61.6 ng/ml (IQR 34.9-132.9) v 16.0 ng/ml (IQR 8.9-25.1), p<0.0001); plasma levels were also significantly higher. When compared with controls, sections of wax embedded lung tissue from patients with ALI showed greater positive staining for thioredoxin in alveolar macrophages and type II epithelial cells. BAL fluid levels of thioredoxin correlated with IL-8 levels in BAL fluid but not with severity of illness scores or mortality. BAL fluid levels of thioredoxin, IL-8, and neutrophils were significantly greater in patients with ALI of pulmonary origin.
CONCLUSIONS: Extracellular thioredoxin levels are raised in patients with ALI, particularly of pulmonary origin, and have a significant positive association with IL-8. Extracellular thioredoxin levels could provide a useful indication of inflammation in ALI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601094      PMCID: PMC2111226          DOI: 10.1136/thx.2005.053041

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  32 in total

1.  Tissue distrubution and subcellular localization of bovine thioredoxin determined by radioimmunoassay.

Authors:  A Holmgren; M Luthman
Journal:  Biochemistry       Date:  1978-09-19       Impact factor: 3.162

2.  Thioredoxin as a key molecule in redox signaling.

Authors:  Hajime Nakamura
Journal:  Antioxid Redox Signal       Date:  2004-02       Impact factor: 8.401

Review 3.  The thioredoxin system--from science to clinic.

Authors:  Stephan Gromer; Sabine Urig; Katja Becker
Journal:  Med Res Rev       Date:  2004-01       Impact factor: 12.944

Review 4.  Pulmonary and extrapulmonary acute respiratory distress syndrome are different.

Authors:  P Pelosi; D D'Onofrio; D Chiumello; S Paolo; G Chiara; V L Capelozzi; C S V Barbas; M Chiaranda; L Gattinoni
Journal:  Eur Respir J Suppl       Date:  2003-08

5.  Serum thioredoxin (TRX) levels in patients with heart failure.

Authors:  C Kishimoto; K Shioji; H Nakamura; Y Nakayama; J Yodoi; S Sasayama
Journal:  Jpn Circ J       Date:  2001-06

6.  Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection.

Authors:  Y Sumida; T Nakashima; T Yoh; Y Nakajima; H Ishikawa; H Mitsuyoshi; Y Sakamoto; T Okanoue; K Kashima; H Nakamura; J Yodoi
Journal:  J Hepatol       Date:  2000-10       Impact factor: 25.083

7.  Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms.

Authors:  S Pomplun; A C Wotherspoon; G Shah; P Goldstraw; G Ladas; A G Nicholson
Journal:  Histopathology       Date:  2002-02       Impact factor: 5.087

Review 8.  Physiological functions of thioredoxin and thioredoxin reductase.

Authors:  E S Arnér; A Holmgren
Journal:  Eur J Biochem       Date:  2000-10

9.  Elevated serum levels of thioredoxin in patients with acute exacerbation of asthma.

Authors:  Yoshiyuki Yamada; Hajime Nakamura; Tetsuya Adachi; Satoshi Sannohe; Hajime Oyamada; Hiroyuki Kayaba; Junji Yodoi; Junichi Chihara
Journal:  Immunol Lett       Date:  2003-04-03       Impact factor: 3.685

Review 10.  Thioredoxin superfamily and thioredoxin-inducing agents.

Authors:  Kiichi Hirota; Hajime Nakamura; Hiroshi Masutani; Junji Yodoi
Journal:  Ann N Y Acad Sci       Date:  2002-05       Impact factor: 5.691

View more
  23 in total

1.  Persistently low plasma thioredoxin is associated with meningococcal septic shock in children.

Authors:  Matthew E Callister; Anne Burke-Gaffney; Gregory J Quinlan; Helen Betts; Simon Nadel; Timothy W Evans
Journal:  Intensive Care Med       Date:  2006-11-18       Impact factor: 17.440

2.  Manipulation of inflammation in ARDS: achievable goal or distant target?

Authors:  S V Baudouin
Journal:  Thorax       Date:  2006-06       Impact factor: 9.139

Review 3.  Redox-based regulation of signal transduction: principles, pitfalls, and promises.

Authors:  Yvonne M W Janssen-Heininger; Brooke T Mossman; Nicholas H Heintz; Henry J Forman; Balaraman Kalyanaraman; Toren Finkel; Jonathan S Stamler; Sue Goo Rhee; Albert van der Vliet
Journal:  Free Radic Biol Med       Date:  2008-03-27       Impact factor: 7.376

4.  Protective effects of thoracic epidural anesthesia on hypoxia-induced acute lung injury in rabbits.

Authors:  Lijun Wang; Jing Cang; Zhanggang Xue
Journal:  Exp Ther Med       Date:  2016-03-11       Impact factor: 2.447

5.  A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.

Authors:  Ramesh K Ramanathan; Joe J Stephenson; Glen J Weiss; Linda A Pestano; Ann Lowe; Alton Hiscox; Rafael A Leos; Julie C Martin; Lynn Kirkpatrick; Donald A Richards
Journal:  Invest New Drugs       Date:  2011-08-24       Impact factor: 3.850

6.  A genome-wide expression analysis in blood identifies pre-elafin as a biomarker in ARDS.

Authors:  Zhaoxi Wang; Douglas Beach; Li Su; Rihong Zhai; David C Christiani
Journal:  Am J Respir Cell Mol Biol       Date:  2008-01-18       Impact factor: 6.914

Review 7.  Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor.

Authors:  Susannah K Leaver; Niall S MacCallum; Vasisht Pingle; Matthew B Hacking; Gregory J Quinlan; Timothy W Evans; Anne Burke-Gaffney
Journal:  Intensive Care Med       Date:  2009-09-15       Impact factor: 17.440

8.  Redox responses in patients with sepsis: high correlation of thioredoxin-1 and macrophage migration inhibitory factor plasma levels.

Authors:  Thorsten Brenner; Claudia Rosenhagen; Jochen Steppan; Christoph Lichtenstern; Jürgen Weitz; Thomas Bruckner; Eike O Martin; Ursula Hoffmann; Markus A Weigand; Stefan Hofer
Journal:  Mediators Inflamm       Date:  2010-08-05       Impact factor: 4.711

9.  Protection from lipopolysaccharide-induced lung injury by augmentation of airway S-nitrosothiols.

Authors:  Harvey E Marshall; Erin N Potts; Zachary T Kelleher; Jonathan S Stamler; W Michael Foster; Richard L Auten
Journal:  Am J Respir Crit Care Med       Date:  2009-03-26       Impact factor: 21.405

Review 10.  Redox compartmentalization in eukaryotic cells.

Authors:  Young-Mi Go; Dean P Jones
Journal:  Biochim Biophys Acta       Date:  2008-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.